Welcome to the 4th Annual Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit
Revolutionizing the Development of Extrahepatic Lipid Vehicles
Lipid-based nanoparticles are evolving—faster, safer and more precise than ever. With traditional LNPs struggling to reach tissues beyond the liver, the industry is doubling down on next generation technologies for extra-hepatic. In 2024 alone, Novo Nordisk invested $600M in NanoVation to push genetic medicines further, while Nanite and Saliogen joined forces to pioneer non-viral, lung-targeting nanoparticles.
Formerly known as the Next Gen Lipid-Based Nanoparticle Delivery Summit, the summit is the only industry-dedicated event laser-focused on extrahepatic targeting, delivery efficiency and scalable manufacturing for mRNA, siRNA, DNA and gene therapies.
Join 80+ delivery experts, CXOs and leading scientists from AstraZeneca, Novo Nordisk, Takeda, Orbital Therapeutics and more for three jam-packed days in Boston this June. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your lipid-based delivery vehicles beyond the liver and into the next generation.
Sessions You Can't Miss:
Your 20+ Expert Speaker Faculty Includes:
Paula Hammond
Vice Provost for Faculty and Institute Professor
Massachusetts Institute of Technology
Top Testimonials:
"I’ve attended Hanson Wade hosted mRNA-LNP related conferences multiple times, and it never fails to impress. These events bring together the most innovative minds from academia and biotech to share groundbreaking research and practical commercialization strategies. The networking opportunities are incredible—this event consistently sparks new ideas, collaborations, and builds impactful business partnerships”
Pengbo Guo, Vice President, CybernaX Bio
“Participating in this meeting is an invaluable opportunity to tackle shared challenges and biological barriers in tissue-specific delivery through collaboration and knowledge exchange. By engaging with experts, we can collectively advance innovative drug delivery strategies, accelerating the development of effective RNA therapeutics and ultimately improving outcomes for patients”
Nahal Habibi, Senior Scientist, Non-Viral Delivery, Orbital Therapeutics
Other Events In the LNP Development Series:
